Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verrica Pharmaceuticals Inc (NQ: VRCA ) 2.080 -0.220 (-9.57%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Verrica Pharmaceuticals Inc < Previous 1 2 3 Next > Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York September 04, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results August 14, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma August 14, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 August 06, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. July 01, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York May 30, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm May 26, 2024 From Bragar Eagel & Squire Via GlobeNewswire VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm May 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts May 15, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results May 13, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Present at Upcoming Investor Conferences May 09, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 May 08, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 27, 2024 From Bragar Eagel & Squire Via GlobeNewswire Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA March 26, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA March 08, 2024 From Kahn Swick & Foti, LLC Via Business Wire Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results February 29, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 February 22, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA February 14, 2024 From Kahn Swick & Foti, LLC Via Business Wire Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition February 05, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services January 29, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma January 05, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts January 04, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™ January 03, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) Near the Top of Equities by Percentage Gain on 12/15 December 15, 2023 Via Investor Brand Network Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan December 15, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London November 10, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results November 09, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 October 25, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.